67582-10-9Relevant academic research and scientific papers
Hydrazone linker as a useful tool for preparing chimeric peptide/ Nonpeptide bifunctional compounds
Dyniewicz, Jolanta,Lipinski, Piotr F. J.,Kosson, Piotr,Lesniak, Anna,Bochynska-Czyz, Marta,Muchowska, Adriana,Tourwe, Dirk,Ballet, Steven,Misicka, Aleksandra,Lipkowski, Andrzej W.
supporting information, p. 73 - 77 (2017/12/12)
The area of multitarget compounds, joining two pharmacophores within one molecule, is a vivid field of research in medicinal chemistry. Not only pharmacophoric elements are essential for the design and activity of such compounds, but the type and length o
Development of novel enkephalin analogues that have enhanced opioid activities at both μ and δ opioid receptors
Yeon, Sun Lee,Petrov, Ravil,Park, Chad K.,Ma, Shou-Wu,Davis, Peg,Lai, Josephine,Porreca, Frank,Vardanyan, Ruben,Hruby, Victor J.
, p. 5528 - 5532 (2008/03/13)
Enkephalin analogues with a 4-anilidopiperidine scaffold have been designed and synthesized to achieve therapeutic benefit for the treatment of pain due to mixed μ and δ opioid agonist activities. Ligand 16, in which a Dmt-substituted enkephalin-like stru
Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides
Liederer, Bianca M.,Fuchs, Tarra,Velde, David Vander,Siahaan, Teruna J.,Borchardt, Ronald T.
, p. 1261 - 1270 (2007/10/03)
Previously, our laboratory showed that the oxymethyl-modified coumarinic acid (OMCA) cyclic prodrug of the opioid peptide DADLE ([D-Ala 2,D-Leu5]-Enk, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH) exhibited low permeation across both the intestinal
Synthesis and pharmacological study of some enkephalin analogs in relation to the plurality of opiate receptors
Audigier,Mazarguil,Gout,Cros
, p. 173 - 177 (2007/10/02)
We have synthesized a series of enkephalin analogs and measured their affinity for each type of 'opiate' receptor, the μ receptor and the δ receptor. Furthermore, we have determined their respective antinociceptive activity after intracerebroventricular i
